Frontlight ResearchEarly access
Not yet taking people in CzechiaPhase 2
Tests a stool bacteria transfer for autism symptoms in children
Tests whether transplanted gut bacteria from stool change core autism symptoms in children.
Key facts
- Who runs it
- Masarykova Univerzita
- Where
- Brno, CzechiaSee the site
- Trial code
- Registry title
- Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 17 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 3 to 12 years with autism spectrum disorder confirmed by a specialist, who speak only a few words.
- Age
- 3 to 12 years
- Sex
- All sexes
- Disease stage
- Autism spectrum disorder confirmed by a clinical psychologist or psychiatrist, with an earlier ADOS-2 result in the ASD range and only minimum verbal ability (ADOS-2 Module 1).
- Earlier treatment
- No new or recently changed behavioural, cognitive or cognitive-behavioural therapy or medicine in the last 30 days. No immunosuppressants, antiplatelet drugs, anticoagulants, antibiotics, probiotics, prebiotics or postbiotics now or in the last 3 months.
Main reasons for not taking part
- Birth defect or primary disease of the digestive tract, including coeliac disease
- Early reaction to food in the medical history
- Cannot take the bowel preparation, for example cannot use liquid medicine
- Cannot have sedation, or had serious problems with sedation before
- Weak immune system, or severe other conditions such as psychosis, epilepsy not controlled by medicine, or severe vision or hearing loss
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 3–12 years
- Diagnosis of ASD confirmed by a clinical psychologist or psychiatrist
- Previous ADOS-2 examination result in the ASD range
- Only minimum verbal ability (i.e. corresponding to ADOS-2, Module 1)
- Informed consent of the parent (legal representative) and willingness to follow all planned study visits and instructions, especially for bowel preparation
Who cannot take part
- Newly initiated or recently changed formal behavioural, cognitive or cognitive-behavioural therapy (less than 30 days before enrolment)
- Expected inability to undergo bowel preparation (e.g. child’s inability to use liquid medication declared by parent)
- Contraindication for common sedative medication, or serious complications of sedation in the patient’s medical history
- Use of antiplatelet drugs, anticoagulants, or systemic antibiotics at present or in the last 3 months
- Newly initiated or recently changed pharmacotherapy (less than 30 days before enrolment)
- Congenital GIT defect or primary GIT disease, incl. medically confirmed coeliac disease (gluten enteropathy)
- Severe co-morbid conditions (e.g. psychosis, epilepsy uncontrolled by medication, presence of severe visual or hearing impairment) that may interact with study procedures (at discretion of the investigator)
- Early reaction to food in the patient’s medical history
- Use of systemic immunosuppressants at present or in the last 3 months, or present medically confirmed immunocompromised status
- Use of probiotics, prebiotics, or postbiotics at present or in the last 3 months
Where in Czechia
- Fakultni nemocnice BrnoBrno, CzechiaNot yet recruiting
About the trial
What the trial wants to find out
The primary objective of the trial is to describe the effect of faecal microbiota transplant (FMT) on autism spectrum disorder core symptoms.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)
- Plain-language title
- Tests a stool bacteria transfer for autism symptoms in childrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 17 March 2026